Latest:
Investigators Explore Immunotherapy for NETs as Incidence Grows
To date, oncologists have not seen much success with immunotherapy for neuroendocrine tumors.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Joshua Richter, MD, Tisch Cancer Center at Mount Sinai
Latest:
Dr Richter on the Current State of Bispecific Antibodies in Multiple Myeloma
Joshua Richter, MD, discusses how bispecific antibodies fit into the current treatment armamentarium for patients with multiple myeloma, highlighting his presentation from the 41st Annual CFS®.
Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center
Latest:
Investigational Agents for Relapsed/Refractory Myeloma
Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Hervé Tilly, MD, PhD
Latest:
Dr. Tilly on Pola-R-CHP in an Asia Subpopulation of Patients With DLBCL
Hervé Tilly, MD, PhD, discusses the efficacy of polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone in an Asia subpopulation of patients with diffuse large B-cell lymphoma.
Michael J Birrer, MD, PhD
Latest:
Dr Birrer on Molecular Stratification in Endometrial Cancer
Michael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.
Asal Rahimi, MD, MS
Latest:
Dr Rahimi on Escalating Preoperative, Single-Fraction Ablative Radiation in HR-Positive Breast Cancer
Asal Rahimi, MD, MS, discusses initial efficacy results from the expanded cohort of a phase 1 dose-escalation study (NCT04040569) evaluating pre-operative, single fraction stereotactic ablative radiation in early-stage, hormone receptor–positive breast cancer.
Christine Duncan, MD, Dana-Farber Cancer Institute
Latest:
Narsoplimab: The Phase 2 Trial
Samer Khaled, MD reviews the design, results, and practical implications of the pivotal phase 2 trial of narsoplimab, a MASP-2 targeted monoclonal antibody under investigation for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplantation.